Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
COSCIENS Biopharma ( (TSE:CSCI) ) has provided an announcement.
On November 14, 2025, COSCIENS Biopharma announced a leadership change with Peter H. Puccetti appointed as Interim CEO, succeeding Anna Biehn. This transition aligns with the company’s efforts to streamline operations and focus on strategic priorities. The company also reported its third-quarter financial results and plans to delist from the Nasdaq Capital Market, maintaining its listing on the Toronto Stock Exchange. These strategic moves are expected to enhance operational efficiency and shareholder value.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life science company specializing in the development of natural, plant-based active ingredients and the commercialization of pharmaceutical and diagnostic products. The company utilizes proprietary manufacturing and extraction technologies to produce ingredients like Avenanthramides and Beta Glucan, widely used in skincare. COSCIENS’ lead pharmaceutical product, Macimorelin, is FDA and EMA approved for diagnosing adult growth hormone deficiency.
Average Trading Volume: 3,897
Technical Sentiment Signal: Sell
Current Market Cap: C$10.07M
Learn more about CSCI stock on TipRanks’ Stock Analysis page.